NO833641L - Medikamenter som omfatter minst ett immunotoksin og minst en enverdig karboksylisk ionofor - Google Patents

Medikamenter som omfatter minst ett immunotoksin og minst en enverdig karboksylisk ionofor

Info

Publication number
NO833641L
NO833641L NO833641A NO833641A NO833641L NO 833641 L NO833641 L NO 833641L NO 833641 A NO833641 A NO 833641A NO 833641 A NO833641 A NO 833641A NO 833641 L NO833641 L NO 833641L
Authority
NO
Norway
Prior art keywords
immunotoxin
monensin
ricin
cytotoxic
chain
Prior art date
Application number
NO833641A
Other languages
English (en)
Norwegian (no)
Inventor
Franz Jansen
Pierre Gros
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NO833641L publication Critical patent/NO833641L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO833641A 1982-02-09 1983-10-06 Medikamenter som omfatter minst ett immunotoksin og minst en enverdig karboksylisk ionofor NO833641L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8202091A FR2521010B1 (fr) 1982-02-09 1982-02-09 Medicaments comportant en tant qu'association au moins une immunotoxine et au moins un ionophore carboxylique monovalent

Publications (1)

Publication Number Publication Date
NO833641L true NO833641L (no) 1983-10-06

Family

ID=9270809

Family Applications (1)

Application Number Title Priority Date Filing Date
NO833641A NO833641L (no) 1982-02-09 1983-10-06 Medikamenter som omfatter minst ett immunotoksin og minst en enverdig karboksylisk ionofor

Country Status (8)

Country Link
US (1) US4767621A (OSRAM)
EP (1) EP0086152B1 (OSRAM)
JP (1) JPS59500272A (OSRAM)
AT (1) ATE19857T1 (OSRAM)
DE (1) DE3363563D1 (OSRAM)
FR (1) FR2521010B1 (OSRAM)
NO (1) NO833641L (OSRAM)
WO (1) WO1983002725A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
CA1314245C (en) * 1984-05-23 1993-03-09 Franz Jansen Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators
FR2564839B1 (fr) * 1984-05-23 1986-11-14 Sanofi Sa Conjugues associant par liaison covalente un ionophore carboxylique monovalent et une macromolecule et leur utilisation comme agents potentialisateurs des immunotoxines
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
US20190046497A1 (en) * 2016-02-14 2019-02-14 Yeda Research And Development Co., Ltd. Methods of modulating protein exocytosis and uses of same in therapy

Also Published As

Publication number Publication date
EP0086152A1 (fr) 1983-08-17
ATE19857T1 (de) 1986-06-15
JPH0534343B2 (OSRAM) 1993-05-21
FR2521010A1 (fr) 1983-08-12
FR2521010B1 (fr) 1985-07-19
WO1983002725A1 (fr) 1983-08-18
JPS59500272A (ja) 1984-02-23
DE3363563D1 (en) 1986-06-26
US4767621A (en) 1988-08-30
EP0086152B1 (fr) 1986-05-21

Similar Documents

Publication Publication Date Title
Selbo et al. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy
DE69529517T2 (de) Kreisförmig permutierte liganden und kreisförmig permutierte chimärische molekülen
DE3280408T2 (de) Krebshemmende heilmittel fuer die behandlung von t-leukaemien, bestehend aus der a-kette des rizinus und einem spezifischen monoklonalen antikoerper.
TWI222863B (en) Synergistic pharmaceutical compositions comprising anthracycline derivatives and anticancer agents
WO1994016729A1 (en) Targeted nitric oxide pathway or nitric oxide synthase modulation
JP4929436B2 (ja) セファロタキシンアルカロイド組成物およびその使用
MX2008014404A (es) Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.
JP5478492B2 (ja) 医薬化合物
WO2018078648A4 (en) Gold nanoparticle based formulation for use in cancer therapy
CN109498627A (zh) 一种治疗肿瘤的药物组合物及其应用
KR20240012592A (ko) 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
AU2002221622B2 (en) Antitumor therapy comprising distamycin derivatives
US20020037328A1 (en) Hexitol compositions and uses thereof
JP2634218B2 (ja) Ａｄｃｃ療法を高める組成物
EP1466614B1 (de) Polypeptid, dessen konjugat doxorubicin enthält, und auf diesem basierende pharmazeutische zusammensetzung
JPH0641423B2 (ja) 細胞毒性薬剤組成物及び細胞毒性薬剤キット
FitzGerald et al. Antitumor activity of a thioether-linked immunotoxin: OVB3-PE
NO834087L (no) Fremgangsmaate for fremstilling av cytotoksiske midler
JPH0534343B2 (OSRAM)
Aiello et al. CBX-12: A low pH targeting alphalex™-exatecan conjugate for the treatment of solid tumors
JP2023550043A5 (OSRAM)
Casellas et al. Immunotoxin enhancers
DE3689299T2 (de) Verwendung von amphipatischen Molekülen zur Radiodarstellung und Therapie mittels monoklonaler oder polyklonaler Antikörperkonjugate.
CN107921134B (zh) 肿瘤基因甲基化调节剂的新用途及抗肿瘤药物
Zylicz et al. In vivo potentiation of cis-diamminedichloroplatinum (II) antitumor activity by pretreatment with sparsomycin